10-Q · May 13, 2026
Zenas BioPharma reported a dismal Q1 2026 with no revenue recognized, down from $10 million in the same period last year. Operating expenses totaled $77.35 million, marking a significant increase compared to $47.33…
Earnings analysis · 10-Q
ZBIO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Zenas reported $1.0 million of second-quarter revenue and diluted EPS of negative $1.77, while the supplied filing text does not provide gross margin, operating margin, operating cash flow, or free cash flow. Liquidity…
Read full summary
Zenas reported $1.0 million of second-quarter revenue and diluted EPS of negative $1.77, while the supplied filing text does not provide gross margin, operating margin, operating cash flow, or free cash flow. Liquidity was $673.9 million as of June 30, 2026, and management expects funding through at least Q2 2029 assuming $48.7 million of ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon. The principal negatives are continued dependence on external financing, $75.0 million of Pharmakon debt, heightened China tariff and supply-chain exposure, and a CFO transition effective September 30, 2026.
Reported figures
- Earnings per share
- $-1.77
What stood out
-
Liquidity runway extends through Q2 2029
Cash, cash equivalents and investments totaled $673.9 million as of June 30, 2026. Management expects this liquidity, together with $48.7 million of third-quarter ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon, to fund operations through at least Q2 2029.
-
Revenue remained limited and EPS was negative
Second-quarter revenue was $1.0 million and diluted EPS was negative $1.77. The filing does not provide prior-year revenue or margin figures in the supplied text, limiting trend analysis.
-
Debt position and financing terms disclosed
The company reported $75.0 million outstanding under the Pharmakon Loan Agreement as of June 30, 2026, with interest accruing at three-month SOFR subject to a 3.25% floor plus 5.75%.
-
No material control deficiencies reported
Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls.
What to watch
-
China tariffs and supply-chain exposure
The company imports certain drug substance, drug product and other components from China, while its current sole obexelimab CMO, WuXi Biologics, operates in China. The filing states that tariffs imposed or announced in April 2026 on patented pharmaceutical products could increase costs and cause supply-chain disruptions.
-
Debt service depends on external financing
The company had $75.0 million outstanding under the Pharmakon Loan Agreement as of June 30, 2026, and states that operations are not expected to generate sufficient cash flow to service debt and fund necessary capital expenditures in the foreseeable future.
-
Variable-rate debt creates interest risk
A 100-basis-point adverse change in market interest rates would increase interest expense on the loan payable by approximately $0.8 million, after considering applicable minimum floors.
-
CFO transition during liquidity-intensive period
Jennifer Fox will leave her CFO and Chief Business Officer roles effective September 30, 2026. Joseph Farmer will become principal financial officer and principal accounting officer effective September 30, 2026 while the company searches for a CFO.
-
Convertible notes may pressure liquidity
The filing states that convertible-note conversions may require cash settlement and could materially adversely affect liquidity. It also notes that conversion-related reclassification could materially reduce reported working capital.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and investments of $673.9 million as of June 30, 2026, together with $48.7 million of third-quarter ATM proceeds and potential $75.0 million milestones from each of Royalty Pharma and Pharmakon, are expected to fund operations through at least Q2 2029.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.